8-K: Salarius Pharmaceuticals Secures Conditional Nasdaq Listing Extension Amidst Compliance Challenges

Salarius Pharmaceuticals, Inc. has been granted a conditional extension by the Nasdaq Hearings Panel to regain compliance with minimum bid price and stockholders' equity requirements, avoiding immediate delisting.

Summary

• Salarius Pharmaceuticals, Inc. received a written notification on June 11, 2025, from The Nasdaq Stock Market LLC that the Nasdaq Hearings Panel granted an extension to regain compliance with Nasdaq Listing Rules 5550(a)(2) (Minimum Bid Price Requirement) and 5550(b)(1) (Equity Standard).
• The extension is contingent on Salarius achieving specific milestones: regaining compliance with the Equity Standard by early July 2025 and the Minimum Bid Price Requirement by early August 2025.
• Failure to satisfy these milestones within the prescribed time periods may result in the revocation of the extension by the Hearings Panel.
• Previously, on April 23, 2025, Salarius received a delisting notice for failing to meet the $1.00 minimum bid price requirement for 30 consecutive business days, and was ineligible for the standard 180-day compliance period due to a reverse stock split within the prior year.
• Additionally, on March 26, 2025, Nasdaq notified Salarius of non-compliance with the $2.5 million minimum stockholders' equity requirement based on its Form 10-K for the year ended December 31, 2024.
• Salarius timely appealed the delisting determination, which stayed the suspension of its securities, and the hearing took place on June 3, 2025.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While the extension granted by Nasdaq is a positive outcome, preventing immediate delisting, it is conditional and highlights ongoing significant financial and operational challenges related to minimum bid price and stockholders' equity. The company is still under pressure to meet strict deadlines, and failure would lead to delisting.

Positives

• The Nasdaq Hearings Panel granted Salarius Pharmaceuticals an extension to regain compliance with listing rules, preventing immediate delisting.
• The appeal process successfully stayed the suspension of Salarius's securities and the filing of Form 25-NSE, allowing the company to continue trading while addressing compliance.

Negatives

• Salarius Pharmaceuticals is currently non-compliant with Nasdaq Listing Rule 5550(a)(2), having a closing bid price below the $1.00 minimum bid price requirement for 30 consecutive business days.
• The company is also non-compliant with Nasdaq Listing Rule 5550(b)(1), failing to maintain a minimum of $2.5 million in stockholders' equity.
• Salarius was not eligible for the standard 180-calendar day compliance period for the minimum bid price requirement due to having effected a reverse stock split during the prior one-year period.
• Failure to meet the specified compliance milestones by early July 2025 (Equity Standard) and early August 2025 (Minimum Bid Price) could result in the revocation of the extension and subsequent delisting.

Risks

• Delisting Risk: If Salarius fails to meet the Equity Standard by early July 2025 and the Minimum Bid Price Requirement by early August 2025, the Nasdaq Hearings Panel may revoke the extension, leading to the delisting of its common stock from The Nasdaq Capital Market.
• Operational Challenges: The underlying issues causing the low stock price and insufficient stockholders' equity (e.g., financial performance, market perception) persist and need to be addressed.
• Reverse Stock Split Impact: A recent reverse stock split did not resolve the bid price issue and prevented eligibility for standard compliance periods, indicating potential ongoing challenges in maintaining stock value.

Future Outlook

Salarius Pharmaceuticals has been granted a conditional extension to regain compliance with Nasdaq listing standards. The company must achieve compliance with the Equity Standard by early July 2025 and the Minimum Bid Price Requirement by early August 2025. Failure to meet these milestones could result in the revocation of the extension and subsequent delisting.

Management Comments

• Salarius timely exercised its right to request a hearing to appeal the delisting determination, which stayed the suspension of Salarius securities and the filing of the Form 25-NSE pending the Hearings Panel's decision.
• The report was signed by Mark J. Rosenblum, Executive Vice President & Chief Financial Officer.

Industry Context

Companies in the biotechnology and pharmaceutical sectors, particularly those in clinical development stages like Salarius, often face significant financial challenges and rely heavily on capital markets. Maintaining Nasdaq listing compliance is crucial for these companies to access capital, maintain investor confidence, and ensure liquidity for their shares. Non-compliance with bid price and equity standards is a common issue for smaller, development-stage biotechs, often reflecting market skepticism about their pipeline, financial runway, or overall business viability. The need for a reverse stock split in the prior year further highlights the company's struggle to maintain its share price.

Comparison to Industry Standards

• Maintaining minimum bid price and stockholders' equity are standard listing requirements across major stock exchanges globally, including Nasdaq.
• For development-stage biotechnology companies, meeting these financial thresholds can be particularly challenging due to high R&D costs, lack of revenue from commercialized products, and reliance on dilutive financing.
• While specific comparable companies are not named in the document, many small-cap biotech firms frequently face similar delisting threats and often resort to reverse stock splits or significant capital raises to regain compliance. Salarius's situation is not unique in this regard within the high-risk, high-reward biotech industry.

Stakeholder Impact

• Shareholders: The extension provides a temporary reprieve from immediate delisting, preserving the liquidity and tradability of their shares on Nasdaq. However, the continued risk of delisting if milestones are not met creates ongoing uncertainty and potential for significant value erosion.
• Employees: Continued listing on Nasdaq can help maintain company stability and morale, but the underlying financial challenges could still impact job security or future growth prospects.
• Creditors: The company's ability to maintain its listing may influence its creditworthiness and access to future financing.

Next Steps

• Regain compliance with the Equity Standard (minimum $2.5 million stockholders' equity) by early July 2025.
• Regain compliance with the Minimum Bid Price Requirement ($1.00 per share) by early August 2025.
• Notify Nasdaq of the achievement of these milestones.

Key Dates

Recommendation

Keywords

Salarius Pharmaceuticals, SLRX, Nasdaq, Delisting, Compliance, Minimum Bid Price, Stockholders' Equity, 8-K Filing, Biotechnology, Pharmaceuticals, Reverse Stock Split, Nasdaq Listing Rules